Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076687 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00076687 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 155 participants.
The verdict
NCT00076687, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
Interventions
- DRUG saline
- BIOLOGICAL botulinum toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2003-10 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076687
The ClinicalTrials.gov registry entry for NCT00076687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which saline is the first listed.
NCT00076687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076687 about?
NCT00076687 is a clinical study titled "Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function". The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
What is the current status of trial NCT00076687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2003-10. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00076687?
The interventions under investigation include: saline (DRUG), botulinum toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00076687?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.